PMID- 29744813
OWN - NLM
STAT- MEDLINE
DCOM- 20180905
LR  - 20181114
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Linking)
VI  - 35
IP  - 6
DP  - 2018 May 9
TI  - Assessment of the methods used to detect HER2-positive advanced extramammary 
      Paget's disease.
PG  - 92
LID - 10.1007/s12032-018-1154-z [doi]
AB  - The human epidermal growth factor receptor 2 (HER2) is recognized as an oncogene 
      as well as a therapeutic target in various cancers. Certain patients with 
      advanced extramammary Paget's disease (EMPD) have also been reported to express 
      HER2, which is therefore considered a therapeutic target for EMPD. However, an 
      accurate methodology to determine HER2-positive EMPD has not been established. To 
      assess the optimal methods for detection of HER2-positive EMPD, 73 EMPD samples 
      were analyzed by immunohistochemical (IHC) staining, fluorescence in situ 
      hybridization (FISH), and the HER2 testing algorithm for breast cancer of the 
      American Society of Clinical Oncology/College of American Pathologists, which 
      combined the results of IHC staining and FISH. The results showed discordance in 
      the rate of positive IHC staining and FISH results. While 68.6% (24/35) of the 
      metastatic samples showed equivocal or positive IHC staining, only 37.1% (13/35) 
      were positive by FISH. To assess the accuracy of these methods, the degree of 
      HER2 expression detected by each method was correlated with the staining profiles 
      of activated downstream signaling pathways involving phosphorylated p44/42 MAPK 
      (Thr202/Tyr204) (p-ERK1/2) and phosphorylated AKT (Ser473) (p-AKT). Among 16 
      lymph node metastasis samples, all HER2-positive samples as determined by the 
      testing algorithm stained positively for both p-ERK1/2 and p-AKT. On the other 
      hand, 10-14.3% of the samples determined by FISH or IHC showed negative staining 
      for p-ERK1/2 and p-AKT. The results showed that combining the results of IHC and 
      FISH according to the HER2 testing algorithm is a useful method for accurately 
      evaluating HER2-positive EMPD.
FAU - Hirai, Ikuko
AU  - Hirai I
AD  - Department of Dermatology, Keio University School of Medicine, 35 Shinano-machi, 
      Shinjuku-ku, Tokyo, 160-8582, Japan.
FAU - Tanese, Keiji
AU  - Tanese K
AUID- ORCID: 0000-0002-1409-6475
AD  - Department of Dermatology, Keio University School of Medicine, 35 Shinano-machi, 
      Shinjuku-ku, Tokyo, 160-8582, Japan. tanese@2001.jukuin.keio.ac.jp.
FAU - Nakamura, Yoshio
AU  - Nakamura Y
AD  - Department of Dermatology, Keio University School of Medicine, 35 Shinano-machi, 
      Shinjuku-ku, Tokyo, 160-8582, Japan.
FAU - Otsuka, Atsushi
AU  - Otsuka A
AD  - Department of Dermatology, Kyoto University School of Medicine, Kyoto, Japan.
FAU - Fujisawa, Yasuhiro
AU  - Fujisawa Y
AD  - Department of Dermatology, University of Tsukuba School of Medicine, Tsukuba, 
      Japan.
FAU - Yamamoto, Yuki
AU  - Yamamoto Y
AD  - Department of Dermatology, Wakayama Medical University School of Medicine, 
      Wakayama, Japan.
FAU - Hata, Hiroo
AU  - Hata H
AD  - Department of Dermatology, Hokkaido University School of Medicine, Sapporo, 
      Japan.
FAU - Fujimura, Taku
AU  - Fujimura T
AD  - Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan.
FAU - Matsushita, Shigeto
AU  - Matsushita S
AD  - Department of Dermato-Oncology/Dermatology, National Hospital Organization 
      Kagoshima Medical Center, Kagoshima, Japan.
FAU - Yoshino, Koji
AU  - Yoshino K
AD  - Department of Dermatology, Tokyo Metropolitan Cancer and Infectious Disease 
      Center Komagome Hospital, Tokyo, Japan.
FAU - Kameyama, Kaori
AU  - Kameyama K
AD  - Department of Pathology, Keio University School of Medicine, Tokyo, Japan.
FAU - Amagai, Masayuki
AU  - Amagai M
AD  - Department of Dermatology, Keio University School of Medicine, 35 Shinano-machi, 
      Shinjuku-ku, Tokyo, 160-8582, Japan.
FAU - Funakoshi, Takeru
AU  - Funakoshi T
AD  - Department of Dermatology, Keio University School of Medicine, 35 Shinano-machi, 
      Shinjuku-ku, Tokyo, 160-8582, Japan.
LA  - eng
GR  - JP17lk0201063/AMED/
PT  - Journal Article
DEP - 20180509
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Algorithms
MH  - Female
MH  - Gene Amplification
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Paget Disease, Extramammary/*enzymology/genetics/pathology
MH  - Receptor, ErbB-2/*biosynthesis/genetics/metabolism
MH  - Signal Transduction
OTO - NOTNLM
OT  - AKT signaling pathway
OT  - Extramammary Paget's disease
OT  - HER2
OT  - MAPK signaling pathway
EDAT- 2018/05/11 06:00
MHDA- 2018/09/06 06:00
CRDT- 2018/05/11 06:00
PHST- 2018/04/10 00:00 [received]
PHST- 2018/05/03 00:00 [accepted]
PHST- 2018/05/11 06:00 [entrez]
PHST- 2018/05/11 06:00 [pubmed]
PHST- 2018/09/06 06:00 [medline]
AID - 10.1007/s12032-018-1154-z [pii]
AID - 10.1007/s12032-018-1154-z [doi]
PST - epublish
SO  - Med Oncol. 2018 May 9;35(6):92. doi: 10.1007/s12032-018-1154-z.